Advances in cardiology: Clinical trial update

Future Cardiology

Volumn 7, Issue 3, 2011, Pages 299-310

  Howe, Andrew J ^a   Shand, James A ^a   Menown, Ian B A ^a  

^a SOUTHERN HEALTH AND SOCIAL CARE TRUST   (United Kingdom)

Author keywords

anticoagulants; antiplatetets; aortic stenosis; atrial fibrillation; biodegradable polymers; everolimus; heart failure; pacing; telemonitoring

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXIBAN; CLOPIDOGREL; ENOXAPARIN; EPLERENONE; FONDAPARINUX; HEPARIN; IVABRADINE; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; UNCLASSIFIED DRUG; WARFARIN;

ACUTE ISCHEMIC SYNDROME; ARTICLE; BRAIN EMBOLISM; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGY; CATHETER THROMBOSIS; DRUG EFFICACY; DRUG MEGADOSE; GENETIC POLYMORPHISM; GENOTYPE; HEART ASSIST DEVICE; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ISCHEMIA; MITRAL ANNULAR IMPLANT; PATENT FORAMEN OVALE DEVICE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SICK SINUS SYNDROME; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; TELEMONITORING; TRANSCATHETER AORTIC VALVE IMPLANTATION;

ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOLOGY; CORONARY ARTERY DISEASE; FACTOR IXA; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; POLYSACCHARIDES; STENTS;

EID: 79958094899     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.11.17     Document Type: Article

References (49)

1. Montalescot G: ATOLL: An international, randomized trial comparing IV enoxaparin with IV unfractionated heparin in primary PCI for ST-elevation myocardial infarction. Presented at: European Society of Cardiology 2010 Congress. Stockholm, Sweden, 30 August 2010.
2. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS5). Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 354, 1464-1476 (2006).
3. Jolly S: FUTURA OASIS 8, a randomized trial comparing two regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients with non-STE-ACS treated with fonadaparinux. Presented at: European Society of Cardiology 2010 Congress. Stockholm, Sweden, 30 August 2010.
4. Schulz S, Mehilli J, Neumann F, et al. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur. Heart J. 31(20), 2482-2491 (2010).
5. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N. Engl. J. Med. 359(7), 688-696 (2008).
6. European Association for Percutaneous Cardiovascular Interventions. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 31, 2501-2555 (2010).
7. Shand JA, Menown IBA, Storey RF: Ticagrelor: from concept to clinical evaluation. Biomark. Med. 5(1), 53-62 (2011).
8. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
9. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121, 512-518 (2010).
10. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749), 1320-1328 (2010).
11. Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363(18), 1704-1714 (2010).
12. Price MJ: Standard versus high-dose clopidogrel according to platelet function testing after PCI: results of the GRAVITAS trial. Presented at: American Heart Association Scientific Sessions 2010. Chicago, IL, USA, 13-17 November 2010.
13. Connolly, S: AVERROES: Apixaban versus acetylsalicylic acid (ASA) to prevent strokes. Presented at: European Society of Cardiology 2010 Congress. Stockholm, Sweden, 30 August 2010.
14. Mahaffey K, Rocket AF: Efficacy and safety of rivaroxaban for the prevention of stroke in subjects with non-valvular atrial fibrillation. Presented at: American Heart Association Scientific Sessions 2010. Chicago, IL, USA, 13-17 November 2010.
15. Nielsen, J: DANPACE: The Danish multicenter randomized trial on single lead atrial versus dual chamber pacing in sick sinus syndrome. Presented at: European Society of Cardiology 2010 Congress. Stockholm, Sweden, 30 August 2010.
16. Nielsen JC, Kristensen L, Henning R, et al. A randomized comparison of atrial and dual-chamber pacing in177 consecutive patients with sick sinus syndrome: echocardiographic and clinical outcome. J. Am. Coll. Cardiol. 42(4), 614-623 (2003). (Pubitemid 37000174)
17. Yu CM, Chan JY, Zhang Q, et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N. Engl. J. Med. 361(22), 2123 (2009).
18. Yu C-M: Pacing to Avoid Cardiac Enlargement (PACE) study. Presented at: European Society of Cardiology 2010 Congress. Stockholm, Sweden, 30 August 2010.
19. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104(21), 2608-2614 (2001). (Pubitemid 33104801)
20. Goette A, ANTIPAF: Angiotensin II antagonist in paroxysmal atrial fibrillation trial. Presented at: European Society of Cardiology 2010 Congress. Stockholm, Sweden, 30 August 2010.
21. The GISSI-AF Investigators: Valsartan for prevention of recurrent atrial fibrillation. N. Engl. J. Med. 360, 1606-1617 (2009).
22. Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM: Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation. JAMA 304(21), 2363 (2010).
23. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT), a randomized placebo-controlled study. Lancet 376, 875-885 (2010).
24. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364(1), 11-21 (2011).
25. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J. Med. 363(25), 2385-2395 (2010).
26. Chaudhry SI, Mattera JA, Curtis JP, et al. Telemonitoring in patients with heart failure. N. Engl. J. Med. 363(24), 2301-2309 (2010).
27. Anker SD: Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled, intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with chronic heart failure. Presented at: American Heart Association Scientific Sessions 2010. Chicago, IL, USA, 13-17 November 2010.
28. Strauer B: STAR Heart Study: the acute and long-term effect of intracoronary stem cell transplantation in 191 patients with chronic heart failure. Presented at: European Society of Cardiology 2010 Congress. Stockholm, Sweden, 30 August 2010.
29. Kromhout D, Giltay EJ, Geleijnse JM: n-3 Fatty Acids and Cardiovascular Events after Myocardial Infarction. N. Engl. J. Med. 363(21), 2015-2026 (2010).
30. Leon H, Shibata MC, Sivakumaran S, et al. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 337, 2931-2931 (2008).
31. Trichon BH, Felker GM, Shaw LK, et al. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am. J. Cardiology 91, 538-543 (2003). (Pubitemid 36263251)
32. Carabello BA: The current therapy for mitral regurgitation. J. Am. Coll. Cardiol. 52(5), 319-326 (2008). (Pubitemid 352002859)
33. Harnek J: EVOLUTION I Study: clinical evaluation of the Edward Lifesciencs percutaneous mitral annuloplasty system for the treatment of mitral regurgitation. Presented at: European Society of Cardiology 2010 Congress. Stockholm, Sweden, 30 August 2010.
34. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 363(17), 1597-1607 (2010).
35. Thomas M, Schymik G, Walther T, et al. Thirty-day results of the SAPIEN aortic bioprosthesis european outcome (SOURCE) registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 122(1), 62-69 (2010).
36. Wendler O: SOURCE registry TAVI: Development of a risk score for transcatheter aortic valve implantation: 1-year outcomes from over 1,000 patients in the SOURCE registry. Presented at: European Society of Cardiology 2010 Congress. Stockholm, Sweden, 30 August 2010.
37. Furlan A: Closure 1, evaluation of the STARFlex® septal closure system in patients with a stroke or TIA due to the possible passage of a clot of unknown origin through a patent foramen ovale (PFO). Presented at: American Heart Association Scientific Sessions 2010. Chicago, IL, USA, 13-17 November 2010.
38. Stone G: SPIRIT IV: Two year results from a prospective randomized trial of everolimus eluting stents compared to paclitaxel eluting stents in patients with coronary artery disease. Presented at: Transcatheter Cardiovascular Therapeutics Conference. Washington, DC, USA, 21-25 September 2010.
39. Kedhi E: COMPARE AMI: Two year outcomes from a prospective randomized trial of everolimus eluting stents compared to paclitaxel eluting stents in patients with STEMI. Presented at: Transcatheter Cardiovascular Therapeutics Conference. Washington, DC, USA, 21-25 September 2010.
40. Jensen L: SORT OUT 4: a prospective randomized trial of everolimus-eluting and sirolimus eluting stents in patients with coronary artery disease. Presented at: Transcatheter Cardiovascular Therapeutics Conference. Washington, DC, USA, 21-25 September 2010.
41. Serruys P: Limus eluted from a durable versus erodable stent coating (LEADERS) 3 year results. Presented at: Transcatheter Cardiovascular Therapeutics Conference. Washington, DC, USA, 21-25 September 2010.
42. Byrne R: Efficacy study of rapamycin- vs. zotarolimus-eluting stents to reduce coronary restenosis (ISAR-TEST-5). Presented at: Transcatheter Cardiovascular Therapeutics Conference. Washington, DC, USA, 21-25 September 2010.
43. Wohrle J: The PERFECT STENT study: a prospective, randomized trial evaluating a paclitaxel eluting balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. Presented at: Transcatheter Cardiovascular Therapeutics Conference. Washington, DC, USA, 21-25 September 2010.
44. Chevalier B: CRISTAL: A prospective randomized trial of sirolimus eluting stents compared to balloon angioplasty for restenosis of drug eluting stents. Presented at: Transcatheter Cardiovascular Therapeutics Conference. Washington, DC, USA, 21-25 September 2010.
45. Teirstein PS: Drug-eluting stent restenosis: an uncommon yet pervasive problem. Circulation 122(1), 5-7 (2010).
46. Columbo A: Angiography Versus (vs) IVUS Optimization (AVIO). Presented at: Transcatheter Cardiovascular Therapeutics Conference. Washington, DC, USA, 21-25 September 2010.
47. Menown IBA: Aspirin, P2Y(12) blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice? Biomark. Med. 5(1), 1-3 (2011).
48. Storey RF: Biology and pharmacology of the platelet P2Y12 receptor. Curr. Pharm. Des. 12(10), 1255-1259 (2006). (Pubitemid 44082134)
49. Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) http://clinicaltrials.gov/ct2/show/NCT00910299